Indegene Ltd - Broadly in-line; maintain buy | Q1FY27 Company Update
Indegene’s Q1FY27 earnings were in-line with our estimates, driven by broad based revenue growth across EMS and ECM segments. Total clients crossed the 100 mark, while the number of USD 10mn+ clients increased to 12 from 10 sequentially.EBITDA margins came in below our estimates at 16.4% (vs 16.9%) on account of higher upfront investment for couple of deals along with investment in AI related programs. The management reiterated its confidence of margins recovering to the historical 18–19% range (excl. other income) over the next few quarters. The company continues to strengthen its AI capabilities and expand its client base beyond the top 20 accounts. We maintain our positive long-term view on the back of healthy deal wins, robust pipeline and strong balance sheet. We maintain our estimates for FY27 and marginally revise our estimates for FY28E to factor in deal wins along with improving margins.
Indegene Ltd. Stock Price Chart
Strong revenue growth supported by broad based execution:
Indegene reported Q1FY27 revenue of Rs 10.6bn, growing 39.7% YoY and 6.0% QoQ (INR terms), marking its strongest Q1 sequential growth in the last four years. CC growth was 2.8% QoQ. Growth was broad-based, led by accounts beyond the top 20 customers, with active clients increasing to 105. The company also added two customers to the US$10–25mn revenue bucket, while revenue contribution from customers outside the top 20 continued to increase, reflecting successful client diversification. Revenue per employee (RPE) strengthened to USD 77,100 - a growth of 3.2%/14.2% QoQ/YoY.
Margins remain under pressure; recovery expected from H2FY27:
EBITDA margins were at 16.4% (+10bps/-300bps QoQ/YoY), on account for investments in workforce transformation and upfront costs associated with large Tectonic and GenAI-led engagements, where revenue recognition is yet to commence. The management reiterated that these investments are temporary and expects EBITDA margins to recover to the historical 18–19% range (excl. other income) by H2FY27, supported by ramp-up of outcome-based contracts, productivity gains from GenAI initiatives and workforce optimization. EMS margins remain resilient, while ECS continues to see margin pressure.
Outlook:
During the quarter, Indegene secured one USD 3–5mn deal, four USD 1–3mn annual contract value deals, along with multiple strategic engagements that have the potential to scale into multi-million-dollar relationships. The company expanded its Tectonic engagement from Germany into Spain while Agentic AI and One-click Regulatory Submission platforms continue to gain customer traction. The management indicated that enterprise AI adoption remains gradual, but customer interest is strong, positioning Indegene well to capture higher-value commercial transformation opportunities.
Valuation, View and Risks:
We expect Indegene grow at a CAGR of 16.7%/ 18.8%/ 25.1% Revenue/ EBITDA/ PAT over FY26-29E. We maintain our estimates for FY27E and upward revise our earnings estimates by 1.9% for FY28E to factor in deal wins along with margin improvement. We have also rolled over our estimates to Q1FY29E EPS of Rs 27.2 and get a TP of Rs 680. We continue to maintain our ‘BUY’ rating. Key Risks: Increased competition globally, slower deal wins, mining of top 20 clients and delayed industry recovery.
Company website: https://www.indegene.com/
| Rating | BUY |
|---|---|
| CMP* | INR 515 |
| Target Price | INR 680 |
| Upside | 32% |
*CMP is as per report published date
Click to download the full Indegene Ltd Q1FY27 Company Update
Analyst:
- Vinay Menon - Senior Research Analyst, Institutional Equities (NISM-201600112117)
- Miloni Mehta - Research Associate, Institutional Equities (NISM-201800127664)
FAQs on Indegene Ltd Q1FY27 Company Update
What is Indegene’s Q1FY27 revenue growth?
Indegene reported Q1FY27 revenue of ₹1,060 crore, representing 39.7% YoY growth in INR terms.
What is the target price for Indegene?
The institutional research report maintains a Buy rating with a target price of ₹680. This is an analyst estimate and is not a guarantee of future returns.
Why did Indegene’s EBITDA margin decline?
EBITDA margin was 16.4%, impacted by upfront costs related to large engagements, workforce transformation and investments in AI programs.
When could Indegene’s margins recover?
Management expects EBITDA margins to recover toward the historical 18–19% range, excluding other income, by H2FY27.
What are the key growth drivers for Indegene?
Key drivers include client diversification, large deal wins, GenAI and agentic AI adoption, Tectonic engagements, regulatory technology and healthcare commercial transformation.
What are the key risks for Indegene?
Important risks include increased global competition, slower deal wins, concentration or mining of major clients, delayed industry recovery and slower-than-expected AI adoption.
Before You Trade, Strengthen Your Foundations with These Guides
- For a stronger understanding of indicators such as RSI, VWAP, and trendlines, check our 👉 Technical Analysis Fundamentals section.
- Want to refine your risk-reward planning? Explore our insights on 👉 Position Sizing & Risk Management Strategies.
- Click here to read more research reports on Indegene
Disclaimer: - Investments in securities market are subject to market risk, read all the related document carefully before investing. https://www.mnclgroup.com/research-disclaimer
